Portal de Periódicos da CAPES

NON-SPECIFIC, RAPIDLY GENERATED CYTOTOXICITY IN LYMPHOCYTES INDUCED BY BCG IN VITRO: NO EVIDENCE OF ENHANCING EFFECT FROM PRECEDING INTERACTION BETWEEN BCG AND TRANSITIONAL CELL LINE CELLS

2000; Lippincott Williams & Wilkins; Volume: 163; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(05)68045-7

1527-3792

Eero Kaasinen, Leena Harju, O Alfthan, Tuomo Timonen,

Neonatal Respiratory Health Research

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Jan 2000NON-SPECIFIC, RAPIDLY GENERATED CYTOTOXICITY IN LYMPHOCYTES INDUCED BY BCG IN VITRO: NO EVIDENCE OF ENHANCING EFFECT FROM PRECEDING INTERACTION BETWEEN BCG AND TRANSITIONAL CELL LINE CELLS EERO S. KAASINEN, LEENA M. HARJU, OLOF S. ALFTHAN, and TUOMO T. TIMONEN EERO S. KAASINENEERO S. KAASINEN More articles by this author , LEENA M. HARJULEENA M. HARJU More articles by this author , OLOF S. ALFTHANOLOF S. ALFTHAN More articles by this author , and TUOMO T. TIMONENTUOMO T. TIMONEN More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68045-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To study short-term events in the mechanism of action of BCG with an emphasis on the interaction between BCG and T24 cell line cells. Materials and Methods: Peripheral blood mononuclear cells (PBMNC) or/and several tumor cell lines were incubated with BCG (Oncotice) using various clinical and subclinical BCG concentrations. Results: 3 h BCG incubation of PBMNC at 107 − 5*105 CFU/ml., followed by a 4 h cytotoxicity test, resulted in a significant augmentation of cytotoxicity of PBMNC against T24 cells, and the augmentation was almost significant at 105 CFU/ml. Overnight BCG incubation of PBMNC further augmented that cytotoxicity at all concentrations down to 104 CFU/ml. The minimum overall time (incubation with BCG + cytotoxicity test), where stimulation of PBMNC could be detected, was only 4 h. The BCG enhanced cytotoxicity of PBMNC could be demonstrated against all the tested cell line cells in a 4 h cytotoxicity test by using a preceding overnight BCG incubation of PBMNC, and against the majority of the cell lines by using a preceding 3 h BCG incubation of PBMNC. No convincing evidence was obtained to support the hypothesis that BCG should be first processed by T24 cells to make these cells more susceptible to cell mediated lysis by PBMNC. Conclusions: Clinical and subclinical concentrations of BCG are directly stimulatory to PBMNC, which become, in a minimum time of a few hours, more capable of killing tumor cells, without a need for preceding interaction between BCG and tumor cells. References 1 : BCG in Perspective: advances in the treatment of superficial bladder cancer. Eur Urol1995; 27: 2. Google Scholar 2 : Suppression of murine tumor growth by immune reaction to the bacillus Calmette-Guérin strain of mycobacterium bovis. J Nat Cancer Inst1972; 48: 245. Google Scholar 3 : Immunotherapy of guinea pig cancer with BCG. Cancer1974; 34: 1532. Google Scholar 4 : Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol1987; 137: 155. Link, Google Scholar 5 : Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol1987; 60: 543. Google Scholar 6 : Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol1990; 144: 53. Link, Google Scholar 7 : Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guerin. Urol Res1989; 17: 299. Google Scholar 8 : Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother1991; 33: 411. Google Scholar 9 : Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopath1986; 40: 375. Google Scholar 10 : Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol1990; 144: 1248. Link, Google Scholar 11 : The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol Immunother1993; 36: 25. Google Scholar 12 : Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol1995; 154: 572. Link, Google Scholar 13 : Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer1992; 69: 537. Google Scholar 14 : Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest1993; 91: 69. Google Scholar 15 : Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol1994; 152: 1275. Link, Google Scholar 16 : Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol1991; 145: 1316. Link, Google Scholar 17 : Morphological aspects of the interaction of bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?. Urol Res1992; 20: 219. Google Scholar 18 : Natural cell-mediated cytotoxicity in normal human peripheral blood lymphocytes and its in vitro boosting with BCG. Cancer Immunol Immunother1983; 15: 17. Google Scholar 19 : Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer1995; 71: 801. Google Scholar 20 : Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol1993; 150: 1932. Link, Google Scholar 21 : On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells. Urol Res1994; 22: 185. Google Scholar 22 : The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother1995; 40: 103. Google Scholar 23 : Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology1996; 87: 339. Google Scholar 24 : BCG induced killer cell activity. Urol Res1988; 16: 351. Google Scholar 25 : BCG induced murine peritoneal exudate cells: Cytotoxic activity against a syngeneic bladder tumor cell line. J Urol1982; 127: 1225. Link, Google Scholar 26 : Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro. Cancer Immunol Immunother1994; 39: 249. Google Scholar 27 : Isolation of mononuclear cells and granulocytes from human blood. Scand. J Clin Invest1988; 97: 77. Google Scholar 28 : In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor. Int J Urol1994; 1: 49. Google Scholar 29 : The effects of BCG on the dog bladder. Invest Urol1975; 12: 423. Google Scholar 30 : Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun1997; 65: 4405. Google Scholar 31 : Bacillus Calmette-Guérin sensitises fresh transitional carcinoma cells and T24 cell line to non-MHC-restricted cytotoxicity in vitro. Br J Urol1993; 72: 897. Google Scholar 32 : Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 of 10 patients. J Urol1998; 159: 1183. Link, Google Scholar 33 : Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res1989; 49: 5469. Google Scholar From the Hyvinkää Hospital, Hyvinkää, the Haartman Institute, Department of Pathology, University of Helsinki, and the Eira Hospital, Helsinki, Finland© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKAASINEN E, HARJU L and TIMONEN T (2018) Inhibition Of Natural, Interleukin-2 Stimulated and Bacillus Calmette-Guerin Enhanced Cytotoxicity With Anti-CD16 AntibodiesJournal of Urology, VOL. 167, NO. 5, (2209-2214), Online publication date: 1-May-2002. Volume 163Issue 1January 2000Page: 317-322 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.KeywordsT24mechanism of actionBCGMetricsAuthor Information EERO S. KAASINEN More articles by this author LEENA M. HARJU More articles by this author OLOF S. ALFTHAN More articles by this author TUOMO T. TIMONEN More articles by this author Expand All Advertisement PDF downloadLoading ...